C. Shepard, L. Finelli, and M. Alter, Global epidemiology of hepatitis C virus infection, The Lancet Infectious Diseases, vol.5, issue.9, pp.558-567, 2005.
DOI : 10.1016/S1473-3099(05)70216-4

K. Awad, . Amd-thorlund, G. Hauser, M. Mabrouk, and C. Gluud, Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials, Hepatology, vol.285, issue.1, pp.1176-1184, 2010.
DOI : 10.1002/hep.23504

A. Neumann, N. Lam, H. Dahari, D. Gretch, T. Wiley et al., Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon- Therapy, Science, vol.282, issue.5386, pp.103-107, 1998.
DOI : 10.1126/science.282.5386.103

U. Mihm, E. Herrmann, C. Sarrazin, and S. Zeuzem, Review article: predicting response in hepatitis C virus therapy, Alimentary Pharmacology and Therapeutics, vol.129, issue.1, pp.1043-54, 2006.
DOI : 10.1136/gut.52.12.1784

A. Talal, R. Ribeiro, K. Powers, M. Grace, C. Cullen et al., Pharmacodynamics of PEG-IFN ?? differentiate HIV/HCV coinfected sustained virological responders from nonresponders, Hepatology, vol.40, issue.5, pp.943-953, 2006.
DOI : 10.1002/hep.21136

H. Miao, X. Xia, A. Perelson, and H. Wu, On Identifiability of Nonlinear ODE Models and Applications in Viral Dynamics, SIAM Review, vol.53, issue.1, 2010.
DOI : 10.1137/090757009

M. Saccomani, An Effective Automatic Procedure for Testing Parameter Identifiability of HIV/AIDS Models, Bulletin of Mathematical Biology, vol.238, issue.2, pp.11-538, 1007.
DOI : 10.1007/s11538-010-9588-2

X. Xia and C. Moog, Identifiability of nonlinear systems with application to HIV/AIDS models, IEEE Transactions on Automatic Control, vol.48, issue.2, pp.330-336, 2003.
DOI : 10.1109/TAC.2002.808494

H. Wu, H. Zhu, H. Miao, and A. Perelson, Parameter Identifiability and Estimation of HIV/AIDS Dynamic Models, Bulletin of Mathematical Biology, vol.48, issue.2, pp.785-799, 2008.
DOI : 10.1007/s11538-007-9279-9

C. Han and K. Chaloner, Design of population studies of hiv dynamics Deterministic and stochastic models of AIDS epidemics and HIV infections with intervention, 2005.

J. Guedj, R. Thiebaut, and D. Commenges, Practical Identifiability of HIV Dynamics Models, Bulletin of Mathematical Biology, vol.48, issue.8, pp.2493-2513, 2007.
DOI : 10.1007/s11538-007-9228-7

URL : https://hal.archives-ouvertes.fr/inserm-00204273

H. Miao, C. Dykes, L. Demeter, J. Cavenaugh, S. Park et al., Modeling and Estimation of Kinetic Parameters and??Replicative Fitness of??HIV-1 from??Flow-Cytometry-Based Growth Competition??Experiments, Bulletin of Mathematical Biology, vol.48, issue.3, pp.1749-1771, 2008.
DOI : 10.1007/s11538-008-9323-4

M. Lavielle, A. Samson, and F. A. Mentré, Maximum Likelihood Estimation of Long-Term HIV Dynamic Models and Antiviral Response, Biometrics, vol.48, issue.1
DOI : 10.1111/j.1541-0420.2010.01422.x

URL : https://hal.archives-ouvertes.fr/inserm-00486937

F. Mentré, A. Mallet, and D. Baccar, Optimal design in random-effects regression models, Biometrika, vol.84, issue.2, pp.429-442, 1997.
DOI : 10.1093/biomet/84.2.429

C. Bazzoli, S. Retout, and F. Mentré, Fisher information matrix for nonlinear mixed effects multiple response models: Evaluation of the appropriateness of the first order linearization using a pharmacokinetic/pharmacodynamic model, Statistics in Medicine, vol.60, issue.14, pp.1940-1956, 2009.
DOI : 10.1111/j.0006-341X.2004.00148.x

URL : https://hal.archives-ouvertes.fr/inserm-00371363

C. Bazzoli, S. Retout, and F. Mentré, Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0. computer methods and programs in biomedicine, pp.55-65, 2010.
URL : https://hal.archives-ouvertes.fr/inserm-00431457

J. Pawlotsky, H. Dahari, A. Neumann, C. Hezode, G. Germanidis et al., Antiviral action of ribavirin in chronic hepatitis C, Gastroenterology, vol.126, issue.3, pp.703-714, 2004.
DOI : 10.1053/j.gastro.2003.12.002

J. Layden-almer, R. Ribeiro, T. Wiley, A. Perelson, and T. Layden, Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin, Hepatology, vol.30, issue.6, pp.1343-1350, 2003.
DOI : 10.1053/jhep.2003.50217

N. Dixit, J. Layden-almer, and T. Layden, Modelling how ribavirin improves interferon response rates in hepatitis C virus infection, Nature, vol.23, issue.7019, pp.922-924, 2005.
DOI : 10.1086/315661

E. Herrmann, A. Neumann, J. Schmidt, and S. Zeuzem, The kinetics of hepatitis C virus, European Journal of Gastroenterology & Hepatology, vol.18, issue.4, pp.85-90, 2000.
DOI : 10.1097/00042737-200604000-00006

J. Guedj, L. Rong, H. Dahari, and A. Perelson, A perspective on modeling hepatitis C virus infection, Journal of Viral Hepatitis, 2010.

A. Atkinson and A. Donev, Optimum Experimental Design, 1992.
DOI : 10.1007/978-3-642-04898-2_434

S. Retout, E. Comets, A. Samson, and F. Mentré, Design in nonlinear mixed effects models: Optimization using the Fedorov???Wynn algorithm and power of the Wald test for binary covariates, Statistics in Medicine, vol.39, issue.28, pp.5162-79, 2007.
DOI : 10.1002/sim.2910

URL : https://hal.archives-ouvertes.fr/hal-00263513

S. Zeuzem, J. Pawlotsky, E. Lukasiewicz, M. Von-wagner, I. Goulis et al., International, multicenter, randomized, controlled study comparing dynamically individualized versus standard treatment in patients with chronic hepatitis C, Journal of Hepatology, vol.43, issue.2, pp.250-257, 2005.
DOI : 10.1016/j.jhep.2005.05.016

K. Sherman, N. Shire, S. Rouster, M. Peters, J. Koziel et al., Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients, Gastroenterology, vol.128, issue.2, pp.313-340, 2005.
DOI : 10.1053/j.gastro.2004.11.059

E. Herrmann, Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon, Hepatology, vol.27, issue.6, pp.1351-1358, 2003.
DOI : 10.1053/jhep.2003.50218

S. Zeuzem, E. Herrmann, J. Lee, J. Fricke, A. Neumann et al., Viral kinetics in patients with chronic hepatitis C treated with standard or peginterferon ??2a, Gastroenterology, vol.120, issue.6, pp.1438-1447, 2001.
DOI : 10.1053/gast.2001.24006

R. Bruno, P. Sacchi, V. Ciappina, C. Zochetti, S. Patruno et al., Viral dynamics and pharmacokinetics of peginterferon alpha-2a and peginterferon alpha-2b in naive patients with chronic hepatitis C: a randomized, controlled study, Antiviral Therapy, vol.9, pp.491-498, 2004.

D. Dahari, A. De-araujo, E. Haagmans, B. Layden, J. Cotler et al., Pharmacodynamics of peg-ifn alpha-2a in hiv/hcv co-infected patients: Implications for treatment outcomes, Journal of Hepatology, 2010.

E. Kuhn and M. Lavielle, Maximum likelihood estimation in nonlinear mixed effects models, Computational Statistics & Data Analysis, vol.49, issue.4, pp.1020-1038, 2005.
DOI : 10.1016/j.csda.2004.07.002

D. Bates and D. Watts, Relative curvature measures of nonlinearity, Journal of the Royal Statistical Society. Series B (Methodological), pp.1-25, 1980.

W. Tan and H. Wu, Deterministic and stochastic models of AIDS epidemics and HIV infections with intervention, World Scientific, 2005.
DOI : 10.1142/5737

B. Jones and J. Wang, Constructing optimal designs for fitting pharmacokinetic models, Statistics and Computing, vol.9, issue.3, pp.209-218, 1999.
DOI : 10.1023/A:1008922030873

S. Retout, F. Mentré, and R. Bruno, Fisher information matrix for non-linear mixed-effects models: evaluation and application for optimal design of enoxaparin population pharmacokinetics, Statistics in Medicine, vol.26, issue.6, pp.2623-2639, 2002.
DOI : 10.1002/sim.1041

A. Neumann, T. Layden, K. Reddy, and R. Levi-drummer, The 2nd phase slope of HCV decline is highly predictive of sustained virologic response following consensus IFN treatment for chronic hepatitis C and is determined by genotype but not dose, Hepatology, vol.32, p.356, 2000.

C. Han, K. Chaloner, and A. Perelson, Bayesian analysis of a population HIV dynamic model. Case studies in Bayesian, statistics, vol.6, pp.223-237, 2002.

C. Han and K. Chaloner, Bayesian Experimental Design for Nonlinear Mixed-Effects Models with Application to HIV Dynamics, Biometrics, vol.50, issue.1, pp.25-33, 2004.
DOI : 10.1038/373117a0

R. Thiébaut, J. Guedj, H. Jacqmin-gadda, G. Chêne, P. Trimoulet et al., Estimation of dynamical model parameters taking into account undetectable marker values, BMC Medical Research Methodology, vol.49, issue.1, pp.1-10, 2006.
DOI : 10.1111/1467-9876.00207

J. Guedj and A. Neumann, Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics, Journal of Theoretical Biology, vol.267, issue.3, pp.330-340
DOI : 10.1016/j.jtbi.2010.08.036

S. Retout, E. Comets, C. Thus, and F. Mentré, Design Optimization in Nonlinear Mixed Effects Models Using Cost Functions: Application to a Joint Model of Infliximab and Methotrexate Pharmacokinetics, Communications in Statistics - Theory and Methods, vol.34, issue.18, pp.3351-3368, 2009.
DOI : 10.1177/0962280206079018

URL : https://hal.archives-ouvertes.fr/inserm-00424247